Get the Stockscreener App
329.82
4.75%
-16.43
After Hours:
329.57
-0.25
-0.08%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $329.82, with a volume of 3.80M.
It is down -4.75% in the last 24 hours and down -6.64% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$346.25
Open:
$332.522
24h Volume:
3.80M
Relative Volume:
1.39
Market Cap:
$178.10B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
23.17
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-4.28%
1M Performance:
-6.64%
6M Performance:
+10.52%
1Y Performance:
+16.22%
1-Day Range:
$324.63
$337.00
1-Week Range:
$324.63
$349.54
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
329.82 | 178.10B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Jennison Associates LLC Sells 91,343 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Margin Expansion In Q1 2026 Tests Cautious Growth Narratives - simplywall.st
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Icon (ICLR) - The Globe and Mail
Amgen Inc. Q1 2026 SEC 10-Q Report: Financial Statements, Defined Terms, and Product Overview 35384155 - Minichart
Amgen Earnings Call Highlights Growth Engines, Tax Risk - TipRanks
Assessing Amgen (AMGN) Valuation After Recent Share Price Weakness And Pipeline Expectations - Yahoo Finance
Amgen Inc (AMGN) Shares Fall 4.8% -- What GF Score of 93 Tells I - GuruFocus
Amgen Inc. stock underperforms Friday when compared to competitors - MSN
AMGN Maintains by Truist Securities -- Price Target Raised to $3 - GuruFocus
Amgen's Shannon Turley Inducted Into National Academy of Sciences - Amgen
Truist Financial Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Amgen: The Quarter Where New Growth Engines Begin to Drown Out the Noise of Patent Expirations - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownShould You Sell? - MarketBeat
Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011. - marketscreener.com
Amgen launches late-stage obesity trial in patients who switch from rival drugs - Endpoints News
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga
IRS Seeks More Taxes From Amgen, Adding to $10.7 Billion Dispute - Bloomberg Law News
Amgen (NASDAQ:AMGN) Price Target Raised to $425.00 - MarketBeat
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains - The Globe and Mail
Apple leads Nasdaq higher at open, Amgen drags on Dow - Proactive financial news
Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis - TradingKey
Amgen 1st-qtr 2026 financials beat expectations - The Pharma Letter
Amgen Inc. (NASDAQ:AMGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Nasdaq leads the pack as Apple impresses, Amgen drags on Dow - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Acquired by Sigma Planning Corp - MarketBeat
New York State Teachers Retirement System Sells 9,158 Shares of Amgen Inc. $AMGN - MarketBeat
BofA Securities raises Amgen stock price target on growth drivers By Investing.com - Investing.com Canada
Strategic Blueprint LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
Danske Bank A S Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Fifth Third Bancorp - MarketBeat
Amgen Inc (AMGN) Q1 2026 Earnings Call Highlights: Strong Produc - GuruFocus
Amgen Inc (AMGN) Q1 2026 Earnings Call Highlights: Strong Product Sales Growth Amidst Competitive Challenges - GuruFocus
AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in Focus - The Globe and Mail
Amgen (NASDAQ:AMGN) Issues Quarterly Earnings Results - MarketBeat
Amgen : C O R R E C T I O N Amgen/ - marketscreener.com
Amgen Doubles Down On Less Frequent MariTide Maintenance Dosing In Obesity - Citeline News & Insights
Amgen (AMGN) Q1 Earnings Exceed Expectations with Strong Revenue Growth - GuruFocus
Sixteen Amgen drugs posted double-digit sales growth in Q1 - Stock Titan
Amgen (NASDAQ: AMGN) posts Q1 2026 profit of $1.8B amid tax, product risks - Stock Titan
/C O R R E C T I O N -- Amgen/ - PR Newswire
Amgen (AMGN) Q1 2026 Earnings Transcript - AOL.com
Amgen (AMGN) Increases Revenue Projections for FY26 - GuruFocus
Amgen Q1 2026 slides: 16 brands fuel growth despite patent headwinds - Investing.com
Amgen Tops Estimates Despite Mixed Performance of Key Drugs - Bloomberg.com
Amgen Q1 Earnings Call Highlights - MarketBeat
Amgen (AMGN) Reports Strong Q1 Revenue Performance - GuruFocus
Amgen (AMGN) Adjusts Revenue Projections for FY26 Upwards - GuruFocus
Earnings call transcript: Amgen Q1 2026 beats expectations, raises guidance - Investing.com
Amgen sales rise 4% in first quarter, broadens weight-loss drug development - KFGO
Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Amgen Q1 2026 beats expectations, raises guidance By Investing.com - Investing.com Canada
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
0.62%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):